Ceftazidime-avibactam for the treatment of febrile neutropenia in HSCT recipients and acute leukemia patients post induction chemotherapy.

ABSTRACT: Febrile neutropenia is a major complication in patients with acute leukemia or those undergoing hematopoietic stem cell transplantation (HSCT). Understanding patient characteristics and susceptibility patterns in febrile neutropenia is essential for appropriate antimicrobial therapy. First-line agents should have Pseudomonas aeruginosa coverage, but with the increase in multi-drug resistant organisms, ceftazidime-avibactam has emerged as a new therapeutic option. This retrospective case-control study included 300 admissions (143 patients) between January 2009 and December 2022. Patients with hematologic neoplasms and patients that underwent HSCT, satisfying the criteria of febrile neutropenia and treated with ceftazidime-avibactam (CAZAVI) were included and compared to controls who receive

SUBMITTER: Abi Frem J 

PROVIDER: S-EPMC11682036 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature